Overview

This trial has been completed.

Condition healthy
Treatments oritavancin, placebo (d5w)
Phase phase 1
Sponsor The Medicines Company
Start date June 2015
End date October 2015
Trial size 14 participants
Trial identifier NCT02470702, MDCO-ORI-15-02

Summary

This protocol describes a double-blind study to evaluate the safety and pharmacokinetics of multiple IV doses of 1200 mg ORBACTIV (oritavancin) in healthy subjects.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification pharmacokinetics study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
Arm
(Experimental)
Subjects randomized to oritavancin will receive four doses (Cohort 1) or eight doses (Cohort 2) of 1200 mg oritavancin, infused intravenously over 3 hours
oritavancin
(Placebo Comparator)
Subjects randomized to placebo will receive four doses (Cohort 1) or eight doses (Cohort 2) of 1000 mL D5W, infused intravenously over 3 hours
placebo (d5w)

Primary Outcomes

Measure
Safety & Tolerability: AEs/SAEs
time frame: From consent until day 110 safety follow up call
Safety & Tolerability: clinical safety laboratory results
time frame: From consent until day 110 safety follow up call
Safety & Tolerability: vital sign measurements
time frame: From consent until day 110 safety follow up call
Safety & Tolerability: ECGs
time frame: From consent until day 110 safety follow up call
Safety & Tolerability: physical examination findings
time frame: From consent until day 110 safety follow up call

Secondary Outcomes

Measure
Pharmacokinetics: AUC0-last
time frame: From pre-dose until 720 hours past last dose
Pharmacokinetics: AUC0-72
time frame: From pre-dose until 72 hours past last dose
Pharmacokinetics: AUC0-∞
time frame: From pre-dose until 720 hours past last dose
Pharmacokinetics: Cmax
time frame: From pre-dose until 720 hours past last dose
Pharmacokinetics: Cmin
time frame: From pre-dose until 720 hours past last dose
Pharmacokinetics: Tmax
time frame: From pre-dose until 720 hours past last dose
Pharmacokinetics: t1/2
time frame: From pre-dose until 720 hours past last dose
Pharmacokinetics: CL
time frame: From pre-dose until 720 hours past last dose
Pharmacokinetics: VSS
time frame: From pre-dose until 720 hours past last dose

Eligibility Criteria

Male or female participants from 18 years up to 55 years old.

Inclusion Criteria: 1. Subject is able to provide written informed consent before initiation of any study-related procedures. 2. Healthy male or female between the ages of 18 and 55 years, inclusive. 3. Body mass index (BMI) < 45 kg/m2. 4. Subject is in good health based on medical history and physical examination findings and has no clinically meaningful safety laboratory abnormalities (CBC, blood chemistry, and urinalysis) or 12 lead ECG results, as assessed by the PI. 5. Vital signs (BP, pulse and temperature) measured at screening/baseline must be within the following ranges: SBP ≥90 to ≤150 mm Hg, DBP ≥45 to ≤90 mm Hg; Heart Rate ≥ 40 to ≤90 bpm (taken after resting in a supine position for at least 5 minutes). 6. Willing to avoid all medications (other than the study drug and acetaminophen/paracetamol for minor aches/pains) during the study. This includes prescription and non-prescription medications, vitamins, herbal supplements, and nutriceuticals. 7. Subject is a non-smoker and is willing to abstain from alcohol/illegal drug use for the duration of the study. 8. If the female subject is surgically sterile, postmenopausal, or, if of childbearing potential, agrees to use at least 2 highly-effective methods of birth control (e.g. prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, barrier methods, abstinence) or male partner sterilization alone for the duration of the study until 60 days after study drug administration. Exclusion Criteria: 1. Has any condition, including findings in the medical history or in pre-study assessments that constitutes a risk or a contraindication for the participation in the study or completing the study. 2. Female subjects of childbearing potential that have a positive test result for human chorionic gonadotropin (hCG) at screening. 3. Female subjects who are nursing. 4. Positive urine test for alcohol and/or for drugs of abuse at screening. 5. Has a history or presence of alcohol/drug abuse within 2 years. Alcohol abuse is defined as regularly consuming >3 units/day (21 units per week for men), >2 units/day (14 units/week) for women. 1 unit of alcohol is defined as a can of 4% beer (330 mL), approximately 190 mL of 6-7% beer (malt liquor), a glass of 40% spirits (30 mL), or a glass of wine (100 mL). 6. History of hypersensitivity to drugs with a similar chemical structure (i.e. glycopeptide antibiotics) to oritavancin or any of its excipients. 7. Blood or plasma donation within the past 2 months. 8. Subjects who participated in other clinical research studies involving the evaluation of other investigational drugs or devices within 30 days or 5 half-lives, whichever is longer, prior to screening and/or unwilling to allow at least two months before participation in another drug trial following the current trial. 9. Treatment with any prescription or OTC drugs, within 2 weeks or 5 half-lives, whichever is longer, or herbal nutritional supplements within 2 weeks of screening, with the exception of acetaminophen/paracetamol for minor aches/pains. Subjects will not be allowed to receive medications for the duration of the study (except the above mentioned acetaminophen/paracetamol). Birth control or other hormone replacement is also permitted as long as it has been taken at a stable dose for at least three months before the screening visit and remains stable for the duration of the study. 10. Males who are unwilling to practice abstinence or use an acceptable method of birth control during the entire study period (i.e. condom with spermicide). 11. Subjects that have any surgical or medical condition that could interfere with the administration of the study drug. 12. Subjects that have known active hepatitis B or C, or human immunodeficiency virus (HIV) infection or has known immune deficiency disease at screening. 13. Subjects that have any condition that would confound or interfere with the assessment of safety. 14. Subjects that have poor IV access as determined by the investigator. Subjects excluded for any of the previous criteria may only be rescreened for participation after discussion with sponsor and principal investigator. 15. Prior exposure to Oritavancin alone or in combination with another product.

Additional Information

Official title A Double-Blind Randomized Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple 1200 mg Dose Intravenous Oritavancin Infusions in Healthy Subjects
Description Oritavancin has been approved in the United States for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSIs) caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms. The purpose of this study is to determine the (a) safety and tolerability and (b) pharmacokinetic profile of multiple doses of Oritavancin given over a 7-8 week period. Cohort 1 will consist of 14 subjects, randomized to receive a total of four doses of either oritavancin or placebo, given once every two weeks in a double-blind fashion. After completion of cohort 1, a Data Safety Monitoring Board will review the blinded safety data and pharmacokinetics (PK) for cohort 1 and determine whether to continue with cohort 2, modify cohort 2 or end the study. The cohorts for this study are sequential. Cohort 2 will consist of 14 subjects, randomized to receive a total of eight doses of either oritavancin or placebo (4 subjects) given once every week in a double-blind fashion.
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by The Medicines Company.